How does a rheumatologist treat a pregnant woman when many medications are not approved for pregnancy or safety data are limited?
Search results for: liver
Highlights from the ACR Review Course 2022
PHILADELPHIA—At ACR Convergence 2022, the much-anticipated ACR Review Course featured talks from eight experts. Topics reflected the heterogeneity of our field and included Sjögren’s disease, spondyloarthritis (SpA), osteoarthritis (OA), paraneoplastic rheumatic syndromes, metabolic bone disease, statin myopathy, Raynaud’s phenomenon and autoinflammatory syndrome. Here, I share highlights from this comprehensive, six-hour session. Sjögren’s Disease Sara S….
What You Need to Know About COVID-19 & Therapies for Rheumatic Diseases
PHILADELPHIA—Since March 2020, the world has been turned upside down by the COVID-19 pandemic. Rheumatologists must understand how to best protect and treat their patients with autoimmune conditions at risk for infection due to immunosuppressive therapy. At ACR Convergence 2022, the session titled, Latest COVID and Rheumatic Disease Therapies: What You Need to Know, provided…
COVID-19: Strategies to Protect Adult & Pediatric Patients
An ACR Convergence 2022 session provided practical updates on ways to best protect pediatric & adult patients with rheumatic disease from COVID-19.
Rheumatic Disease Research in Indigenous Populations
This ACR Convergence 2022 session focused on ways to improve health equity in Indigenous populations.
Duke Researchers Create a Type 1, Type 2 Lupus Disease Model
A new disease model for lupus tackles issues with fatigue and other serious conditions that, although quite common among patients, get less attention because they fall outside classic symptoms associated with inflammation, a debilitating force behind systemic lupus erythematosus (SLE). The model features subtypes to categorize two main groups of symptoms into type 1, typically…
Advocacy Involvement ‘An Antidote to Burnout,’ Says New Government Affairs Chair Christina Downey, MD
The new chair of the ACR’s Government Affairs Committee, Dr. Downey says physicians play a vital role in helping policymakers understand how policies and laws affect patients and the practice of rheumatology.
Phase 2 Trial Results for Sjögren’s Syndrome & SLE Presented in 2nd Plenary Session at ACR Convergence 2022
PHILADELPHIA—At the second Plenary Session of ACR Convergence on Sunday, Nov. 13, speakers shared compelling efficacy and safety results from two phase 2 trials: remibrutinib for Sjögren’s syndrome and deucravacitinib for moderate to severe systemic lupus erythematosus. Remibrutinib in Phase 2 Sjögren’s Syndrome Trial Thomas Dörner, MD, a professor of rheumatology and clinical immunology for…
A New President Takes the ACR Helm: Introducing Douglas White, MD, PhD
In his new role as the 86th president of the ACR, Douglas White, MD, PhD, is excited about the opportunities to serve and energize the organization and members in the coming year.
Case Report: Lupus Nephritis or a Mimic?
Syphilis, an ancient disease caused by the spirochete Treponema pallidum, has been historically referred to as the great mimicker given its heterogenous presentation. Both systemic lupus erythematosus (SLE) and syphilis can have multi-systemic involvement. Both parvovirus B19 and syphilis have been reported to cause histologic features similar to those seen in lupus nephritis. We present…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 130
- Next Page »